192 related articles for article (PubMed ID: 12428265)
1. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.
Cisternas M; Gutiérrez M; Jacobelli S
Arthritis Rheum; 2002 Nov; 46(11):3107-8; author reply 3108-9. PubMed ID: 12428265
[No Abstract] [Full Text] [Related]
2. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy.
Izzi S; Francesconi F; Visca P; Altieri A; De Mutiis C; Trevisan G; Bonifati C
Dermatol Online J; 2010 May; 16(5):16. PubMed ID: 20492833
[TBL] [Abstract][Full Text] [Related]
3. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
[No Abstract] [Full Text] [Related]
4. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
5. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
[No Abstract] [Full Text] [Related]
6. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.
Nikas SN; Voulgari PV; Takalou IP; Katsimbri P; Drosos AA
Ann Rheum Dis; 2005 Nov; 64(11):1665-7. PubMed ID: 16227426
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of infliximab for the treatment of psoriatic arthritis.
Ritchlin C
Nat Clin Pract Rheumatol; 2006 Jun; 2(6):300-1. PubMed ID: 16932707
[No Abstract] [Full Text] [Related]
8. Vasculitis, vitiligo, thyroiditis, and altered hormone levels after anti-tumor necrosis factor therapy.
Lahita RG; Vernace MA
J Rheumatol; 2011 Mar; 38(3):579-80. PubMed ID: 21362795
[No Abstract] [Full Text] [Related]
9. Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Glück et al.
Aparicio AG; Muñoz-Fernández S; Bonilla G; Miralles A; Cerdeño V; Martín-Mola E
Arthritis Rheum; 2003 Jun; 48(6):1764-5; author reply 1765-6. PubMed ID: 12794847
[No Abstract] [Full Text] [Related]
10. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
[No Abstract] [Full Text] [Related]
11. [TNF-alpha inhibitors].
Fain O
Rev Prat; 2003 Nov; 53(18):1989-90. PubMed ID: 15008210
[No Abstract] [Full Text] [Related]
12. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
13. TNFalpha therapy in psoriatic arthritis and psoriasis.
Mease P
Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
[No Abstract] [Full Text] [Related]
14. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
[No Abstract] [Full Text] [Related]
15. Guillain-Barré syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature.
Silburn S; McIvor E; McEntegart A; Wilson H
Ann Rheum Dis; 2008 Apr; 67(4):575-6. PubMed ID: 18349168
[No Abstract] [Full Text] [Related]
16. Tuberculosis after anti-TNF therapy: a continuous learning process.
Psichogiou M; Sfikakis PP; Kontos F; Daikos GL
Scand J Rheumatol; 2012 Oct; 41(5):401-3. PubMed ID: 22803620
[No Abstract] [Full Text] [Related]
17. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
Lehnen M; Goos M; Dissemond J
Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
[No Abstract] [Full Text] [Related]
18. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
[TBL] [Abstract][Full Text] [Related]
19. Do TNF-blockers reduce or induce uveitis?
Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
[No Abstract] [Full Text] [Related]
20. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
Goodemote P; Jamieson B; Hoffman R
J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
[No Abstract] [Full Text] [Related]
[Next] [New Search]
